EuroBiotech: More Articles of Note

> The U.K drugmaker AstraZeneca said it has penned a deal to sell Germany’s Grünenthal rights to its migraine treatment Zomig for all markets outside of Japan. AZ will get $200 million when the deal is done and up to $102 million in additional payments if targets are hit. FiercePharma story

> Novo Nordisk has won EU approval for its new haemophilia drug Reflixia and is planning its first European launches in the fourth quarter. Statement

> Takeda has broken ground on construction of a new €40 million expansion of its production facility in Dublin, Ireland. The high containment production plant will be dedicated to producing Takeda’s blood cancer peptide Ninlaro. Irish Examiner story

> Ipsen has appointed Natixis to purchase 160,000 of its shares, or about 0.2% of the share capital, over the next 2 months. The stock will be allocated to cover its free performance share allocation plan. Release

> In a Joint Declaration published this week and co-signed by European biopharma R&D lobby group EFPIA, 23 EU business signatories are calling on the European Commission, the European Parliament and the Council of the European Union to develop an “ambitious” next EU Research & Innovation Framework Programme. Public letter